Ameneh Eshghinejad: The First 72 Hours After SAH Are Critical for Balancing the Risks of Rebleeding and Thromboembolism
Ameneh Eshghinejad, Intensive Care Nurse at Milad hospital, shared a post on LinkedIn:
”The 72-Hour Rule After SAH… is not just a timeline. It’s a decision that can change a life.
In the ICU, we live in the space between two risks:
Rebleeding… versus Thromboembolism
After an aneurysmal subarachnoid hemorrhage (SAH), the question isn’t if anticoagulation is needed – it’s when it becomes safe enough.
And that’s where many clinicians hesitate.
Here’s the practical bedside approach:
0–24 hours:
No anticoagulation.
Mechanical prophylaxis only (IPC).
Your priority equals protect the brain.
24–48 hours:
Start VTE prophylaxis (low-dose heparin or enoxaparin)
Only if:
- No active bleeding
- Imaging is stable
Greater than or equal to 72 hours:
Now we reassess everything.
If the patient is:
- Aneurysm secured (clipped/coiled)
- Clinically and radiologically stable
- No hematoma expansion
This is your green light for therapeutic anticoagulation.
The Bedside Rule you should never forget:
Secured plus Stable plus 72 hours equals Go (carefully)
But here’s the part we don’t always talk about…
I once cared for a patient post-SAH—young, previously healthy.
We delayed anticoagulation, fearing rebleeding.
On day 4, everything looked ‘stable.’
But before escalation… they developed a massive pulmonary embolism.
That moment stays with you.
Because in critical care, waiting is also a decision.
And sometimes… it costs more than acting.
This is why precision matters.
Not just protocols. Not just guidelines.
But clinical judgment, timing, and courage to reassess.”

Stay updated with Hemostasis Today.
-
Nov 18, 2026, 01:45Shikha Jha: My Takeaways from the 4th GANSID International Congress
-
Nov 18, 2026, 01:34Zeeshan Ahmed Khattak: Treatment of Fever and Neutropenia in Hematology/Oncology and Hematopoietic Cell Transplant Patients
-
Nov 17, 2026, 23:45Cajetan Reichardt: LAAO vs. OAC in AF – Balancing Nonprocedural Bleeding and Ischemic Stroke Risk
-
Nov 17, 2026, 23:42Brian Tegtmeyer: Expanding Pre-Hospital Administration of Low-Titer O Positive Whole Blood
-
Nov 17, 2026, 23:41Mansi Kala: Advancing Hematology – From Evidence to Clinical Excellence
-
Nov 17, 2026, 23:40Nathan Connell: Registered for the WFH Comprehensive Care Summit 2027 in Prague
-
Nov 17, 2026, 23:38Yaariv Khaykin: Does Reducing AF Burden After Ablation Change the Need for Anticoagulation?
-
Nov 17, 2026, 23:38Amos Gitonga Mbaabu: Strengthening Care and Advocacy for Haemophilia and SCD across Southern Africa
-
Nov 17, 2026, 23:35Muhammad Sameed Altaf: A Decade of Working Together for Thalassemia Awareness and Patient Support